Adverse event profiles of drug-induced liver injury caused by antidepressant drugs: a disproportionality analysis

• Published in: Therapeutic advances in drug safety Vol. 15; p. 20420986241244585
• Main Authors: Jiang, Aidou, Wei, Chunyan, Zhu, Weiwei, Wu, Fengbo, Wu, Bin
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01.01.2024; SAGE Publishing
• Subjects: Original Research; drug-induced liver injury; antidepressants; FAERS database; adverse events
• ISSN: 2042-0986; 2042-0994
• DOI: 10.1177/20420986241244585

Antidepressants are widely used to manage depression and other psychiatric diseases. A previous study revealed that hepatotoxicity was the main adverse event related to antidepressants. Therefore, drug-induced liver injury (DILI) caused by antidepressants deserves more attention. To investigate DILI adverse events reported due to antidepressant use in the United States Food and Drug Administration Adverse Events Reporting System (FAERS) database. A disproportionality analysis of spontaneously reported adverse events was conducted to assess the association between antidepressant drugs and DILI. FAERS data from 1 January 2004 to 31 December 2021 were compiled and analyzed using the reporting odds ratio (ROR) and information component (IC). As per the FAERS database, of the 324,588 cases that were administered antidepressants, 10,355 were identified as cases with DILI. Among the identified 42 antidepressants, nefazodone (  = 47, ROR = 7.79, IC = 2.91), fluvoxamine (  = 29, ROR = 4.69, IC = 2.20), and clomipramine (  = 24, ROR = 3.97, IC = 1.96) had the highest ROR for cholestatic injury; mianserin (  = 3, ROR = 21.46, IC = 3.99), nefazodone (  = 264, ROR = 18.67, IC = 3.84), and maprotiline (  = 15, ROR = 5.65, IC = 2.39) for hepatocellular injury; and nefazodone (  = 187, ROR = 12.71, IC = 0.48), clomipramine (  = 35, ROR = 2.07, IC = 0.26), and mirtazapine (  = 483, ROR = 1.96, IC = 0.94) for severe drug-related hepatic disorders. Only nefazodone elicited hepatic failure signals (  = 48, ROR = 18.64, IC = 4.16). There are limited reports on the adverse reactions of relatively new antidepressant drugs, such as milnacipran, viloxazine, esketamine, and tianeptine, and those not approved by the Food and Drugs Administration, such as reboxetine and agomelatine. A significant association was observed between DILI and nefazodone. Duloxetine and clomipramine were associated with three DILI categories, except hepatic failure. The disproportionality analysis cannot conclude on a definite causal link between antidepressants and DILI. Additional research is required to assess new-generation antidepressants for their propensity to cause DILI.